Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST
Outcomes in Japanese patients were consistent with the ASC4FIRST overall population. Asciminib may be a therapy of choice for Japanese patients with CML.
Authors
- Rokuro Osako
- Tatsunori Goto (ORCID: https://orcid.org/0000-0002-0314-9498)
- Kaoru Hatano
- Michiko Ichii
- Yoshikane Kikushige (ORCID: https://orcid.org/0000-0002-7721-1696)
- Nobuhiro Hiramoto (ORCID: https://orcid.org/0000-0002-0472-6680)
- Takanori Teshima (ORCID: https://orcid.org/0000-0002-0941-271X)
- Akihiro Tomita (ORCID: https://orcid.org/0000-0002-5391-1399)
- Takayuki Ikezoe (ORCID: https://orcid.org/0000-0002-7858-278X)
- Naoto Takahashi (ORCID: https://orcid.org/0000-0002-6758-3787)
- Kamel Malek
- Hirohisa Nakamae (ORCID: https://orcid.org/0000-0003-4203-990X)
- Hirokazu Tanaka (ORCID: https://orcid.org/0000-0002-4897-351X)
- Makoto Aoki (ORCID: https://orcid.org/0000-0001-7984-3809)
- Keita Kirito (ORCID: https://orcid.org/0000-0001-5682-2132)
- Yasunori Ueda (ORCID: https://orcid.org/0000-0002-0514-106X)
- Satoshi Ito (ORCID: https://orcid.org/0000-0002-4647-563X)
Institutions
- Novartis (Switzerland) (CH)
- Fukushima Medical University (JP)
- Fujita Health University (JP)
- Jichi Medical University (JP)
- Akita University (JP)
- Hokkaido University (JP)
- Kurashiki Central Hospital (JP)
- Kyushu University Hospital (JP)
- Novartis (Japan) (JP)
- Japanese Red Cross Nagoya Daiichi Hospital (JP)
- Osaka University Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Yamagata University Hospital (JP)
- Osaka City University Hospital (JP)
- University of Yamanashi (JP)
- Kindai University (JP)
Publication Details
- Journal
- International Journal of Hematology
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1007/s12185-025-04014-z
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharma